



Company Announcement no. 11/2015

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, 10 April 2015

Warrant Programme - New Articles of Association

In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors of Veloxis Pharmaceuticals A/S has on 27 March 2015 issued 4,748,092 warrants for the subscription of nominally DKK 474,809.20 shares in the Company.

The amendment of the Articles of Association associated with the issue of warrants has today been registered with the Danish Business Authority. The new Articles of Association for Veloxis Pharmaceuticals A/S are attached.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino
President & CEO
Phone: +1 732 321 3202
Email: wjp@veloxis.com

Johnny Stilou
EVP, Chief Financial Officer
Phone: +45 30 53 33 64
Email: jst@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.